Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1841-1860 of 3,900 trials

Cirrhosis Treatment: Efinopegdutide Study

We are testing efinopegdutide in adults with compensated cirrhosis caused by metabolic dysfunction. The study aims to see if it can reduce liver fat and improve liver health compared to a placebo.

Non-alcoholic Steatohepatitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesEndocrinologyHepatology

Acute Graft Versus Host Disease: Siltuximab Treatment

We are studying the effects of siltuximab combined with corticosteroids for patients with severe acute graft versus host disease affecting the liver and gut. The goal is to see if this treatment is effective and safe for first-line therapy.

Acute Graft Versus Host Disease (GVHD)>2 yearsEfficacy phase (II)HematologyInternal Medicine

Cytoreductive Surgery: Albumin and Ringer Lactate Study

We are testing whether a combination of 20% albumin and Ringer Lactate improves recovery after surgery for patients with peritoneal carcinosis. This study compares it to Ringer Lactate alone to see which is more effective.

Peritoneal Carcinomatosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsInternal MedicineOncology

Prolonged Seizures: Staccato Alprazolam Study

We are investigating whether Staccato Alprazolam is safe and effective for quickly stopping prolonged seizures in individuals aged 12 and older. The study compares its effects to a placebo to assess its benefits.

Prolonged Seizure3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Cognitive Impairment in Parkinson's: Donepezil Study

We are studying whether donepezil can improve cognitive function in people with mild cognitive impairment due to Parkinson's disease. The trial will also evaluate its effects on mental health and quality of life.

Parkinson's Disease6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Lymphoma Treatment: MK-3475A Study

We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.

Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Primary Mediastinal Large B-cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Gastric Cancer: New Drug Combinations

We are studying new combinations of medications alongside chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The goal is to see if these combinations improve treatment outcomes and safety.

Gastric AdenocarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Dexamethasone for Advanced Multiple Myeloma

We are studying a free treatment regimen of Dexamethasone for patients with advanced relapsed or refractory multiple myeloma. The goal is to see how well it works in improving response rates and quality of life.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Advanced High-Grade Osteosarcoma: OMO-103 Treatment Study

We are testing a new drug, OMO-103, to see if it can help treat advanced high-grade osteosarcoma in patients aged 12-15. The study will assess its safety and how it impacts the patients' quality of life.

Metastatic Osteosarcoma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Acute Myeloid Leukemia: Venetoclax and Azacitidine with Cusatuzumab

We are studying whether adding cusatuzumab to standard treatment helps newly diagnosed AML patients who can't have intensive therapy. This trial will also look at the safety and effectiveness of this combination.

Acute Myeloid LeukemiaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Solid Tumors: IDE397 Treatment Study

We are evaluating a new drug, IDE397, for adults with advanced solid tumors to see how safe it is and how the body responds to it. This study aims to gather important information about its effects on cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Neuroendocrine Tumors: Lutathera® Treatment Study

We are studying whether additional cycles of Lutathera® can help patients with new progression of intestinal well-differentiated neuroendocrine tumors. This trial compares the treatment to active monitoring to see which approach is more effective.

Neuroendocrine Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Systemic Sclerosis Prevention: Clopidogrel Study

We are investigating if Clopidogrel can reduce the risk of developing systemic sclerosis in patients with specific immune conditions and Raynaud phenomenon. The study compares its effects to a placebo over several years.

Raynaud Phenomenon>2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

The LIFE-MET Study: Metformin and Lifestyle Changes in Early Puberty

We are investigating how Metformin and lifestyle interventions may influence growth and development in girls with overweight and early puberty. The study looks at changes in body composition and pubertal progression.

Precocious Puberty and Overweight1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Sedation Methods in TAVR Procedures

We are comparing different sedation techniques for patients undergoing Transcatheter Aortic Valve Replacement. The goal is to see if one method reduces breathing problems and confusion after the procedure.

Aortic Stenosis1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyGastroenterologyInternal MedicineOtolaryngologyPsychiatry

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology